Procyrion Appoints Andrew Davis as Chief Commercial Officer

December 5, 2025—Procyrion, Inc., a medical device company developing solutions for cardiac and renal impairment, including the Aortix percutaneous mechanical circulatory support (pMCS) device, announced the appointment of Andrew Davis as Chief Commercial Officer.

According to Procyrion, Davis will lead the company’s therapy development with a focus on trial enrollment, key opinion leader engagement, podium strategy, and advancing all early market development activities for future commercialization of the Aortix pMCS. Before joining Procyrion, Davis served as Chief Commercial Officer at Silk Road Medical and spent 15 years at Medtronic. He has also held senior commercial roles at Endologix and 3M’s Advanced Wound Therapy Group.

In November 2023, the company announced commencement of enrollment in the DRAIN-HF pivotal trial of the Aortix technology in patients with acute decompensated heart failure who are unresponsive to standard medical therapy.

“Andy’s deep cardiovascular experience and proven track record of launching category-creating therapies makes him an exceptional addition to the company as enrollment in our DRAIN-HF pivotal trial continues to positively progress,” said Eric S. Fain, MD, President and Chief Executive Officer of Procyrion. “Patients with diuretic-resistant heart failure who have failed currently available therapies remains a significant unmet need and an underserved, large market opportunity. Andy’s leadership will be instrumental as we strengthen therapy development efforts and build the foundation needed to bring the Aortix pump to patients and physicians.”